Previous 10 | Next 10 |
Providers of molecular diagnostic testing services may see some action today on the heels of the FDA's approval for Loxo Oncology's VITRAKVI (larotrectinib) since it is the first cancer drug that will require prospective patients to have their DNA sequenced. More news on: Biocept, Inc., My...
Invitae Corporation (NVTA) Q3 2018 Results Conference Call November 07, 2018 04:30 PM ET Executives Laura D'Angelo - Investor Relations Sean George - Chief Executive Officer Shelly Guyer - Chief Financial Officer Bob Nussbaum - Chief Medical Officer Lee Bendekgey - Chief Oper...
Invitae (NYSE: NVTA ): Q3 GAAP EPS of -$0.45 beats by $0.02 . Revenue of $37.4M (+106.6% Y/Y) beats by $2.6M . Shares +5.8% . Press Release More news on: Invitae, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018 . Based on progress in the quarter, Invitae is raising its...
AAOI , ADT , ALB , ALRM , AMBC , ANGI , ANSS , ARNA , ATO , AVID , AVLR , AYX , BREW , CABO , CARG , CASA , CISN , CSGS , CSOD , CTRP , CVNA , CYBR , DVA , ECPG , EDIT , ENS , ENV , ET , EVC , EVRG , FARM , FG , FLO , FLS , FOSL , GDOT , GKOS , HK , HO...
SAN FRANCISCO , Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals , the leading RNAi therapeutics company, to provide genetic testing at no cos...
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc. (NASDAQ:A...
SAN FRANCISCO , Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that d...
SAN DIEGO , Oct. 17, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The da...
SAN FRANCISCO , Sept. 11, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018 . "We are pleased to welcome Chitra Nayak to our...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...